| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth |
| 15 Jul 2026 |
8-K: Other Events
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy |
| 09 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Purpose. Axsome Therapeutics, Inc., a Delaware corporation (the “Company” or “Axsome”), hereby establishes the Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan (the “Plan”). The Plan is intended to encourage and m... |
| 09 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 Annual Meeting of Stockholders of Axsome Therapeutics, Inc. (the “Company”) held on June 5, 2026 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company: |
| 03 Jun 2026 |
8-K: Other Events
NEW YORK, June 3, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved ... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth |
| 30 Apr 2026 |
8-K: Other Events
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease |
| 01 Apr 2026 |
8-K: Other Events
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions |
| 23 Feb 2026 |
8-K: Results of Operations and Financial Condition
Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% year-over-year growth |
| 17 Feb 2026 |
8-K: Other Events
NEW YORK, February 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has ente... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively |
| 31 Dec 2025 |
8-K: Other Events
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth |
| 20 Aug 2025 |
8-K: Other Events
On August 19, 2025, Axsome Therapeutics, Inc. (the “Company”) received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Apotex Inc. (“Apotex”), providing notification to the Company that Apotex has submitted an Abbre... |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially |
| 10 Jun 2025 |
8-K: Other Events
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults |
| 09 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2025 Annual Meeting of Stockholders of Axsome Therapeutics, Inc. (the “Company”) held on June 6, 2025 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company: |
| 09 Jun 2025 |
8-K: Other Events
NEW YORK, June 09, 2025 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to F... |
| 27 May 2025 |
8-K: Other Events
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. |
Loading...